ENvue MedicalFEED -8.77%34 ROC (Joel Greenblatt) % is -5,762.76% as of Mar. 2026. GuruFocus rates FEED with a GF Score™ of 34/100 and a GF Value™ of $5.13 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, ENvue Medical ranks worse than 98.22% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ENvue Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5,762.76%.
The historical rank and industry rank for ENvue Medical's ROC (Joel Greenblatt) % or its related term are showing as below:
FEED'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61157.14 Med: -10595.4 Max: -541.94
Current: -5210.97
During the past 13 years, ENvue Medical's highest ROC (Joel Greenblatt) % was -541.94%. The lowest was -61157.14%. And the median was -10595.40%.
FEED's ROC (Joel Greenblatt) % is ranked worse than 98.22% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs FEED: -5210.97
ENvue Medical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 30.00% per year.
ENvue Medical (NAS:FEED) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
ENvue Medical ROC (Joel Greenblatt) % Related Terms
ENvue Medical ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ENvue Medical's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FEED vs BTCY, LUDG, AMIX: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, ENvue Medical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENvue Medical ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ENvue Medical's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -5,762.76% mean?
ENvue Medical (FEED) has a ROC (Joel Greenblatt) % of -5,762.76% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ENvue Medical and its competitors. According to the industry distribution chart, ENvue Medical ranks #826 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 98.2%.
Is ENvue Medical's ROC (Joel Greenblatt) % too high?
ENvue Medical's current ROC (Joel Greenblatt) % is -5,762.76%. Based on the distribution chart, ENvue Medical ranks #826 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ENvue Medical has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's ROC (Joel Greenblatt) % compare to BTCY and LUDG?
According to the Medical Devices & Instruments industry distribution chart, ENvue Medical ranks #826 out of 841 companies for ROC (Joel Greenblatt) %. This places ENvue Medical in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 3.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ENvue Medical and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENvue Medical's current ROC (Joel Greenblatt) % is -5,762.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
Based on GuruFocus' analysis, ENvue Medical (FEED) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $0.52 — trading 89.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is -5,762.76%. ENvue Medical's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For ENvue Medical (FEED), the current ROC (Joel Greenblatt) % is -5,762.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ENvue Medical (FEED) Overvalued in 2026?
Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued.
The current stock price of $0.52 is trading 89.8% below its estimated GF Value™ of $5.13.
GuruFocus considers ENvue Medical to be Possible Value Trap.
Key valuation signals for FEED:
ROC (Joel Greenblatt) %: -5,762.76%
GF Value™: $5.13 vs. price of $0.52 (89.8% below fair value)
No single metric tells the full story. See the FEED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
34GF Score
Get the complete analysis for FEED
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEED has been successfully added to your 
